Meibomian gland obstruction

Meibomian gland obstruction refers specifically to blockage at the opening(s) of the meibomian glands along the eyelid margin. This prevents normal secretion of lipids into the tear film. The resulting deficiency in lipid layer leads to increased evaporation of tears and contributes significantly to dry eye syndrome. Obstruction may result from thickened/hardened secretions ("inspissation"), ductal epithelial changes including keratinization/hypertrophy, chronic inflammatory processes such as blepharitis/mebomitis/mebomionanitis, age-related changes in acinar structure/functionality, hormonal influences especially post-menopause in women, contact lens wear interference with normal blinking/gland expression mechanisms—and certain medications that alter lipid production. Obstructive MGD manifests clinically with symptoms including dryness/grittiness/burning/redness/blurry vision/crusting around lids/light sensitivity/foreign body sensation/watery eyes/styes/chalazia/corneal erosions if severe[1][2][3][4]. It often coexists with other lid margin diseases like blepharitis. Diagnosis relies on slit-lamp examination showing blocked/loss-of-function glands at lid margin; sometimes imaging modalities are used. Therapeutic approaches focus on improving outflow through warm compresses/massage/lid hygiene/intense pulsed light therapy/topical/oral anti-inflammatories/artificial tears—but there are no direct pharmacologic agents that bind/interact specifically with an entity called “meibomian gland obstruction” because it describes pathology/anatomy rather than a discrete druggable molecule/receptor/enzyme/transporter/etc.[2][3]. In summary: “Meibomian gland obstruction” should be classified as an anatomical/pathological condition—not as a canonical therapeutic target molecule/receptor/enzyme/transporter/etc.—and thus does not fit standard structured data fields intended for druggable targets[8].

Other names

Meibomian gland dysfunction (MGD)Obstructive MGDMeibomitisMeibomianitis

Not applicable at the molecular level; treatments aim to reduce inflammation, improve oil quality/secretion from glands, or relieve symptoms. For example: Antibiotics/tetracyclines reduce bacterial load and have anti-inflammatory properties. IPL devices use light energy to melt obstructed secretions and reduce peri-glandular inflammation. Cyclosporine reduces ocular surface inflammation.